NEW YORK, Oct. 17 (GenomeWeb News) - Epitome Biosystems said today that it has received a two-year, $500,000 Phase II Small Business Innovation Research grant from the National Science Foundation to support the development of an antibody array that will measure phosphoproteins from three cell signaling pathways.
The award follows a Phase I SBIR that the company received in May 2004 to demonstrate feasibility of its EpiTag technology platform for phosphoprotein analysis. During this phase of the award, the company said that it developed high-affinity antibodies for peptide tags identified for proteins in the MapK signaling pathway, and used the antibodies in an array format to measure protein phosphorylation.
Epitome said that the new award will enable it to develop commercial products with expanded array content to encompass three cell signaling pathways.
For further details about Epitome's technology and its commercialization plans, see this week's ProteoMonitor.